Hospital
Beebe Medical Center, INC.
Beebe Medical Center, INC. was paid $29.31M by Medicaid between Jan 2018 and Dec 2024, across 342 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoBEEBE MEDICAL CENTER, INC.
LEWES, DE 19958
LEWES, DE 19958
33aNPI1821196486assigned 09/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.31M
24GClaims876,073
24DCodes billed342
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 268,425 | $1.61M | |
| 2019 | 204,121 | $3.75M | |
| 2020 | 149,885 | $7.21M | |
| 2021 | 59,191 | $3.42M | |
| 2022 | 77,335 | $5.43M | |
| 2023 | 70,745 | $5.02M | |
| 2024incomplete | 46,371 | $2.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 25,610 | 23,349 | $3.51M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 11% | 15,913 | 15,456 | $3.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 23,747 | 21,039 | $3.03M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.4% | 439 | 417 | $1.28M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 4,679 | 4,006 | $1.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 10,889 | 8,455 | $1.06M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.3% | 4,989 | 3,430 | $978K |
| 80050 | General health panel | 2.5% | 17,010 | 15,989 | $737K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 12,733 | 7,588 | $541K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 5,375 | 4,830 | $482K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 5,525 | 5,232 | $464K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 4,686 | 3,916 | $416K |
330 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 15,652 | $406K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 11,735 | $346K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.1% | 8,029 | $318K |
| 80053 | Comprehensive metabolic panel | 1.1% | 33,985 | $308K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.0% | 1,083 | $298K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,286 | $292K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,057 | $278K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,930 | $278K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,169 | $276K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,449 | $268K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,246 | $260K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,243 | $246K |
| G0378 | Hospital observation service, per hour | <1% | 3,097 | $244K |
| 36415 | Collection of venous blood by venipuncture | <1% | 96,213 | $238K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,683 | $215K |
| 87081 | <1% | 15,102 | $192K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,291 | $188K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,797 | $187K |
| 97597 | <1% | 3,822 | $186K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,793 | $178K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,845 | $175K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,652 | $170K |
| 80061 | Lipid panel | <1% | 14,477 | $164K |
| 84484 | <1% | 9,755 | $161K | |
| 96376 | <1% | 5,682 | $159K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,238 | $156K |
| 87631 | <1% | 4,732 | $152K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,290 | $142K |
| 87581 | <1% | 1,179 | $140K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,348 | $133K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,040 | $130K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,065 | $121K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,562 | $120K |
| 93458 | <1% | 159 | $120K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,822 | $118K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 257 | $112K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,661 | $112K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,530 | $111K |
| 87077 | <1% | 6,724 | $111K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,123 | $110K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,921 | $105K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,892 | $103K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,108 | $100K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 829 | $100K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,937 | $97K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,723 | $91K |
| 93970 | <1% | 570 | $89K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 472 | $88K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,804 | $86K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,885 | $86K |
| 83735 | <1% | 8,577 | $84K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,446 | $84K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,367 | $84K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,327 | $77K |
| 93971 | <1% | 734 | $76K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,151 | $75K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,686 | $71K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 710 | $69K |
| 71250 | <1% | 924 | $69K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,321 | $69K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,348 | $68K |
| 81001 | <1% | 12,460 | $61K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 145 | $52K |
| 87486 | <1% | 1,179 | $51K | |
| 83690 | <1% | 6,628 | $50K | |
| 73564 | <1% | 1,774 | $48K | |
| 83880 | <1% | 1,829 | $47K | |
| 73630 | <1% | 2,107 | $46K | |
| 87186 | <1% | 4,448 | $44K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,707 | $41K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,460 | $41K |
| 84439 | <1% | 4,323 | $41K | |
| 94664 | <1% | 1,497 | $40K | |
| C1769 | Guide wire | <1% | 1,115 | $39K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 954 | $38K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,409 | $37K |
| 82947 | <1% | 7,671 | $36K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,069 | $35K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,179 | $33K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,832 | $33K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 634 | $32K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 778 | $32K |
| 84702 | <1% | 2,051 | $32K | |
| 82728 | <1% | 2,569 | $32K | |
| 73610 | <1% | 1,426 | $30K | |
| 87480 | <1% | 2,004 | $30K | |
| 87660 | <1% | 2,004 | $30K | |
| 87510 | <1% | 2,004 | $30K | |
| 77066 | Tomosynthesis, mammo | <1% | 342 | $30K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,368 | $30K |
| 88142 | <1% | 1,820 | $30K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 365 | $30K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 375 | $30K |
| 80306 | <1% | 1,665 | $30K | |
| 73130 | <1% | 1,382 | $28K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 541 | $28K |
| 76536 | <1% | 666 | $27K | |
| J3490 | Unclassified drugs | <1% | 2,396 | $26K |
| 81025 | <1% | 1,907 | $26K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 842 | $26K |
| 73030 | <1% | 1,316 | $26K | |
| 97161 | <1% | 778 | $25K | |
| 93880 | <1% | 278 | $25K | |
| 88342 | <1% | 1,010 | $24K | |
| 94760 | <1% | 4,603 | $23K | |
| 87040 | <1% | 1,878 | $23K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,068 | $23K |
| 80076 | <1% | 1,397 | $22K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,726 | $22K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,645 | $22K |
| 84703 | <1% | 2,722 | $22K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,057 | $22K |
| 85610 | <1% | 4,452 | $21K | |
| 82607 | <1% | 1,795 | $20K | |
| 72100 | <1% | 947 | $20K | |
| 93017 | <1% | 859 | $19K | |
| 93041 | <1% | 1,232 | $19K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,723 | $19K |
| 76642 | <1% | 535 | $19K | |
| 86140 | <1% | 3,578 | $18K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,117 | $18K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 884 | $18K |
| 88341 | <1% | 351 | $18K | |
| 87070 | <1% | 1,798 | $18K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 501 | $17K |
| 83550 | <1% | 2,310 | $17K | |
| 83540 | <1% | 2,624 | $16K | |
| 83605 | <1% | 1,510 | $16K | |
| 73110 | <1% | 802 | $16K | |
| 85380 | <1% | 1,968 | $16K | |
| 86803 | <1% | 1,287 | $15K | |
| 70486 | <1% | 290 | $15K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,063 | $15K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,687 | $15K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 241 | $13K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 170 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,384 | $13K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 150 | $13K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $13K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,999 | $12K |
| 81003 | <1% | 3,542 | $12K | |
| 72110 | <1% | 575 | $12K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,913 | $12K |
| 76801 | <1% | 107 | $12K | |
| 86850 | <1% | 2,227 | $12K | |
| 73502 | <1% | 675 | $11K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 90 | $11K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 382 | $11K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 584 | $10K |
| 97162 | <1% | 395 | $10K | |
| 74018 | <1% | 786 | $10K | |
| 82550 | <1% | 1,616 | $10K | |
| 85730 | <1% | 1,696 | $10K | |
| 87046 | <1% | 684 | $10K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 32 | $10K |
| 82043 | <1% | 1,653 | $10K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,821 | $9K |
| 93016 | <1% | 1,132 | $9K | |
| 87632 | <1% | 94 | $9K | |
| 88304 | <1% | 852 | $9K | |
| 86780 | <1% | 1,105 | $8K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 697 | $8K |
| 86901 | <1% | 2,602 | $8K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 290 | $8K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 76 | $8K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 221 | $8K |
| 85027 | <1% | 2,494 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 86 | $8K |
| 86900 | <1% | 2,297 | $8K | |
| 82746 | <1% | 662 | $7K | |
| 85652 | <1% | 2,823 | $7K | |
| 87340 | <1% | 1,148 | $7K | |
| 84100 | <1% | 1,984 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,551 | $7K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 253 | $7K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 945 | $7K |
| 87899 | <1% | 509 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 30 | $6K |
| 93018 | <1% | 1,137 | $6K | |
| 90715 | <1% | 282 | $6K | |
| 77080 | <1% | 284 | $6K | |
| 97010 | <1% | 771 | $6K | |
| 93922 | <1% | 124 | $6K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 266 | $6K |
| 80074 | <1% | 153 | $6K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 185 | $6K |
| 73080 | <1% | 320 | $6K | |
| 97116 | <1% | 480 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 628 | $5K |
| 96367 | <1% | 336 | $5K | |
| 94060 | <1% | 285 | $5K | |
| 86618 | <1% | 690 | $5K | |
| 86038 | <1% | 846 | $5K | |
| 72050 | <1% | 208 | $5K | |
| 87481 | <1% | 76 | $5K | |
| 70491 | <1% | 15 | $5K | |
| 82565 | <1% | 1,501 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 224 | $5K |
| 82784 | <1% | 631 | $4K | |
| 87205 | <1% | 1,370 | $4K | |
| 84146 | <1% | 200 | $4K | |
| 72141 | <1% | 26 | $4K | |
| 76775 | <1% | 204 | $4K | |
| 83021 | <1% | 243 | $4K | |
| 82977 | <1% | 918 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,117 | $4K |
| 76870 | <1% | 70 | $4K | |
| 83516 | <1% | 437 | $4K | |
| 83020 | <1% | 243 | $4K | |
| 83655 | <1% | 559 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 80 | $4K |
| 12001 | <1% | 88 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,784 | $3K |
| 84460 | <1% | 908 | $3K | |
| 84550 | <1% | 775 | $3K | |
| 82570 | <1% | 446 | $3K | |
| 94729 | <1% | 228 | $3K | |
| 84156 | <1% | 593 | $3K | |
| 87045 | <1% | 410 | $3K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 314 | $3K |
| 83525 | <1% | 465 | $3K | |
| 73140 | <1% | 378 | $3K | |
| 73590 | <1% | 150 | $3K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 13 | $2K |
| 82150 | <1% | 421 | $2K | |
| 86235 | <1% | 74 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 294 | $2K |
| 93321 | <1% | 69 | $2K | |
| 83615 | <1% | 627 | $2K | |
| 99406 | <1% | 406 | $2K | |
| 87015 | <1% | 569 | $2K | |
| 84403 | <1% | 196 | $2K | |
| 93325 | <1% | 70 | $2K | |
| 10060 | <1% | 31 | $2K | |
| 84425 | <1% | 28 | $2K | |
| 83001 | <1% | 113 | $2K | |
| 82950 | <1% | 515 | $2K | |
| 72040 | <1% | 124 | $2K | |
| 82248 | <1% | 421 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 4,743 | $2K |
| 72070 | <1% | 138 | $2K | |
| 96417 | <1% | 64 | $2K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 42 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 859 | $2K |
| 82803 | <1% | 101 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 19 | $2K |
| 87329 | <1% | 189 | $2K | |
| 87449 | <1% | 176 | $2K | |
| 86706 | <1% | 365 | $1K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 246 | $1K |
| 86430 | <1% | 426 | $1K | |
| 85014 | <1% | 755 | $1K | |
| 83002 | <1% | 61 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 153 | $1K |
| 86762 | <1% | 323 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 36 | $1K |
| 85018 | <1% | 594 | $1K | |
| 80069 | <1% | 135 | $1K | |
| 87328 | <1% | 159 | $1K | |
| 84153 | <1% | 187 | $1K | |
| 59025 | Fetal non-stress test | <1% | 56 | $1K |
| 86665 | <1% | 183 | $1K | |
| 73090 | <1% | 63 | $1K | |
| 87324 | <1% | 157 | $1K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 198 | $1K |
| 90686 | <1% | 80 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 170 | $951.44 |
| 83970 | <1% | 54 | $800.08 | |
| 71101 | <1% | 81 | $779.98 | |
| 86664 | <1% | 155 | $767.14 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 692 | $745.94 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 113 | $737.56 |
| 86255 | <1% | 204 | $732.66 | |
| 85007 | <1% | 813 | $685.89 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $658.72 |
| 83883 | <1% | 67 | $615.19 | |
| 90732 | <1% | 53 | $580.38 | |
| 73562 | <1% | 13 | $579.24 | |
| 82247 | <1% | 82 | $524.74 | |
| 84145 | <1% | 22 | $439.96 | |
| 86039 | <1% | 58 | $417.58 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 61 | $404.78 |
| 87641 | <1% | 66 | $319.61 | |
| 86376 | <1% | 13 | $281.33 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 70 | $276.98 |
| 74150 | <1% | 17 | $243.88 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 15 | $241.93 |
| 12002 | <1% | 13 | $239.73 | |
| 0296T | <1% | 186 | $228.48 | |
| 84450 | <1% | 419 | $223.68 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 399 | $223.14 |
| 84481 | <1% | 143 | $217.37 | |
| 93226 | <1% | 56 | $183.23 | |
| 84165 | <1% | 97 | $170.87 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 53 | $160.45 |
| A9270 | Non-covered item or service | <1% | 12,845 | $159.87 |
| 73522 | <1% | 16 | $156.18 | |
| 93225 | <1% | 58 | $129.31 | |
| 86481 | <1% | 15 | $125.22 | |
| 99152 | <1% | 28 | $121.69 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 426 | $119.93 |
| 89055 | <1% | 15 | $117.25 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 34 | $91.44 |
| 93923 | <1% | 31 | $88.03 | |
| 80164 | <1% | 12 | $59.07 | |
| 84402 | <1% | 44 | $58.55 | |
| 85347 | <1% | 147 | $53.68 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 59 | $51.90 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 67 | $47.30 |
| 82272 | <1% | 57 | $38.54 | |
| 84155 | <1% | 65 | $37.08 | |
| 74022 | <1% | 26 | $30.63 | |
| 82105 | <1% | 30 | $28.03 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 187 | $27.85 |
| 84436 | <1% | 99 | $22.11 | |
| 80178 | <1% | 17 | $17.78 | |
| 85045 | <1% | 14 | $10.74 | |
| 86308 | <1% | 14 | $8.65 | |
| 86003 | <1% | 15 | $7.02 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 483 | $3.95 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 78 | $0.02 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 692 | $0.02 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 673 | $0.02 |
| 36430 | 0% | 22 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 60 | $0.00 |
| 84480 | 0% | 51 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 57 | $0.00 |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 0% | 35 | $0.00 |
| 12011 | 0% | 12 | $0.00 | |
| 87210 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKENNEDY, RYAN (SVP AND CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Beebe Physician Network INC. | Lewes, DE | $19.69M |
| Holy Name EMS | Teaneck, NJ | $919K |
| Beebe Medical Center, INC. | Millsboro, DE | $559K |
| Optimal Home Care LLC | Pensacola, FL | $41K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.